The Science Behind Hydrolyzed Type I Collagen Fragments

About Type 1 CollagenThe use of collagen to progress the healing of acute, surgical and chronic wounds is well accepted among clinicians. The use of hydrolyzed collagen in these areas presents a unique opportunity based on the science of how collagen is broken down and incorporated by the body.

About Type 1 Collagen

Native Type 1 collagen is a large protein molecule that is fragmented naturally as a component of wound healing. This breakdown of Type 1 native collagen occurs by proteinases — such as matrix metalloproteinases (MMPs) — and is an essential and normal component for wound healing and scar formation. The fragments produced as a result of this breakdown (hydrolyzation) are amino acid sequences with active sites indispensable for cell membrane binding to cells such as fibroblasts.

How the Body Uses Collagen

How the Body Uses CollagenCollagen-derived fragments are involved in multiple cellular functions, including cell shape and differentiation, migration, and synthesis. The fragment-attachment sites are chemotactic for a variety of cells responsible for creating granulation tissue. These exposed amino acid fragments are much smaller in size than native collagen. The process of hydrolyzing collagen into fragments for commercial applications is proprietary since the specific process of hydrolysis can affect not only the size of the fragments, but also the physiochemical and biological properties of the end product.

To learn more about surgical and wound care products that contain hydrolyzed collagen, visit SanaraMedTech.com.

References: 

David Brett. A Review of Collagen and Collagen-based Wound Dressings. Wounds. 2008;20(12):347-356. Jeffrey J. Metalloproteinases and tissue turnover. Wounds. 1995;7(Suppl A):13A-22A.

León-López A, Morales-Peñaloza A, Martínez-Juárez VM, Vargas-Torres A, Zeugolis DI, Aguirre-Álvarez G. Hydrolyzed Collagen-Sources and Applications. Molecules. 2019;24(22):4031.

Susan has 30+ years of clinical experience across the continuum of care. Her experience includes direct patient care in critical care and wound care. She has demonstrated clinical and sales leadership roles with wound management organizations such as Healogics, and industry experience with companies such as HealthPoint. Her broad experience from bedside to innovation and industry has provided a unique perspective that she has shared as a consultant and educator. She has been actively involved with the Wound, Ostomy, Continence Society and has many years of service on the board of directors for the Association for the Advancement of Wound Care, and the American Board of Wound Management of which she also served as President. She is currently vice-chair for the American Board of Wound Management Foundation.